Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
|
|
- Bartholomew Hamilton
- 6 years ago
- Views:
Transcription
1 Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of North Carolina This program is made possible with support from an education grant from Eli Lilly Oncology, who had no role in the development of its content. 1
2 Disclosures Research Support Lilly, Genentech, Pfizer, Celgene, Abraxis, Synta, Imclone Speaker s Bureau Lilly, Genentech This activity is supported by a grant from Lilly Drug Names Used in the Presentation Avastin = Bevacizumab Erbitux = Cetuximab Alimta = Pemetrexed Tarceva = Erlotinib Taxotere = Docetaxel Iressa = Gefitinib 2
3 Paradigms Established in Advanced NSCLC Platinum-based chemotherapy improves survival in the 1 st line setting The benefit of platinum-based therapy is achieved early and prolonging therapy beyond 3-4 cycles does not yield clinically relevant benefits The addition of selected targeted agents to platinum-based therapy in the 1 st line setting improves survival (bevacizumab, cetuximab) Selected single agents improve survival when administered after platinum-based therapy Chemotherapy has a palliative effect in symptomatic patients across multiple lines of therapy All chemotherapy agents have toxicity, costs and the inconvenience of adhering to a treatment/assessment schedule We do NOT cure this disease; chronicity with acceptable toxicity is our goal Paradigms Not Established in Advanced NSCLC The value continuation of bevacizumab or cetuximab beyond the end of chemotherapy truly provides The role of biomarkers in making routine treatment decisions in daily clinical practice (EGFR mutations excluded) The optimal surveillance strategy during a treatment break (between lines of therapy) The most appropriate treatment strategy in times of multiple active agents and three lines of FDA-approved therapies (i.e., the timing of 2 nd and 3 rd line therapies) The concept of exposure to multiple lines of therapy (from one and done to 3 strikes before you are retired ) 3
4 NCCN Guidelines for Advanced NSCLC 1 st line Platinum-based doublet + bevacizumab or cetuximab Pemetrexed-based therapy for non-squames Erlotinib for EGFR mutants Maintenance Continuation or Switch 2nd Line Docetaxel, Pemetrexed (non-squames) or Erlotinib 3 rd Line Erlotinib Agents tested in the 2 nd line treatment of advanced NSCLC (Phase III) FDA approved (US) - Docetaxel - Pemetrexed - Erlotinib Phase III tested - Gefitinib - Topotecan (oral) - Vinflunine - Vinorelbine - Ifosfamide Cytotoxic agents Targeted agents (EGFR) 4
5 Considerations Regarding Maintenance Versus 2 nd Line (and beyond) Therapy Agents approved based on survival (BR.21 and TAX 317) and palliative advantage Historically, 2 nd line has been given at the time of disease progression Maintenance* Continuation Biologic agent given initially with CT should be continued until PD or unacceptable toxicity (bevacizumab, cetuximab) Switch Use of a new agent not initially part of the original CT (docetaxel, pemetrexed, erlotinib) in non- PD patients following 4 cycles of therapy *NCCN Guidelines modified by MA Socinski Timing of Second Line Therapy in Advanced NSCLC Chemotherapynaïve stage IIIB/IV NSCLC Platinum-based doublet 4 cycles (Bevacizumab ATLAS) R A N D O M I Z E Immediate 2 nd line therapy Docetaxel (Fidias) Pemetrexed (Ciuleanu) Erlotinib (SATURN) Erlotinib (ATLAS) Delayed 2 nd line therapy Docetaxel (Fidias) MD Choice (JMEN) MD Choice (SATURN) MD Choice(ATLAS) Is this maintenance, sequential, prolonged duration or just earlier use of effective second-line therapy? 5
6 Timing of Second Line Therapy in Advanced NSCLC Chemotherapynaïve stage IIIB/IV NSCLC Platinum-based doublet 4 cycles (Bevacizumab ATLAS) Early PD or DLT patients drop out R A N D O M I Z E Immediate 2 nd line therapy Docetaxel (Fidias) Pemetrexed (Ciuleanu) Erlotinib (SATURN) Erlotinib (ATLAS) Delayed 2 nd line therapy Docetaxel (Fidias) MD Choice (JMEN) MD Choice (SATURN) MD Choice(ATLAS) Is this maintenance, sequential, prolonged duration or just earlier use of effective second-line therapy? Fidias Trial Eligibility & Treatment Plan Patient Eligibility NSCLC Stage IIIb/IV Chemonaïve ECOG PS = 0-2 CNS Mets allowed Primary endpoint: Overall Survival HR: 1.43 GC Phase Gemcitabine, 1000 mg/m 2, Days 1, 8 Carboplatin AUC 5, Day 1 Every 21 days. 4 cycles CR, PR SD R A N D O M I Z E Immediate Docetaxel 75mg/m 2 day 1, every 21 days until progression or maximum of 6 cycles Delayed Docetaxel Best Supportive Care, then start therapy at PD 75mg/m 2 on day 1, every 21 days, until PD or 6 cycles Fidias P et al. J Clin Oncol
7 Patient Disposition Chemonaϊve Stage IIIb/IV NSCLC N = 562 GC Phase N = 552 (388 received 4 cycles) ORR 29% SD, PR, CR N = 307 Immediate N = 153 Randomized Immediate Treated N = 142 Treated Off Study N = 245 Delayed N = 154 Delayed Treated N = 91 Progression-Free Survival Total Randomized Population Proportion Surviving Please note: the PFS curves only showed up Immediate to 24 months Delayed LR since very (n=153) (n=154) few patients left without PD/survival p-value Median 24 PFS months after 6.5 randomization. 2.8 months (4.4, 7.2) (2.6, 3.4) < (95% CI) 12-month PFS, % (95% CI) 20% (13, 26) 9% (5, 14) 0.0 therapy Delayed Immediated Progression Free Survival (months) I: D Patients at Risk 7
8 Overall Survival Total Randomized Population Survival Probability Median OS, mos (95% CI) 12-mo survival (95% CI) Immediate (n=153) 11.9 (10.0, 13.7) 48.5% (39.9, 57.1) Delayed (n=154) 9.1 (8.0, 11.2) 38.3% (30.0, 46.5) LR p-value Overall Survival Time (in Months) Patients at Risk I: D: Survival for Patients Actually Receiving Docetaxel on Immediate & Delayed Arms (Fidias) MST (months) N Immediate Delayed 8
9 JMEN Maintenance Pemetrexed Study Design Belani CP et al. ASCO 2009, abstr #8000 Double-blind, Placebo-controlled, Multicenter, Phase III Trial Stage IIIB/IV NSCLC ECOG PS prior cycles of gem, doc, or tax + cis or carb, with CR, PR, or SD Randomization factors: gender PS stage best tumor response non-platinum drug brain mets 2:1 Randomization Pemetrexed 500 mg/m 2 (d1,q21d) + BSC (N=441)* Primary Endpoint = PFS Secondary = OS, RR, DCR, Tox Placebo (d1, q21d) + BSC (N=222)* *B 12, folate, and dexamethasone given in both arms Progression-Free Survival Progression-free Probability Placebo 2.0 mos HR=0.60 (95% CI: ) P < Pemetrexed 4.0 mos Time (months) 9
10 Overall Survival (Intent-to-treat Population) Survival Probability Placebo 10.6 mos HR=0.79 (95% CI: ) P =0.012 Pemetrexed 13.4 mos Time (months) Overall Survival by Histology Non-squamous (n=481) Squamous (n=182) Survival Probability HR=0.70 (95% CI: ) P =0.002 Placebo 10.3 mos Pemetrexed 15.5 mos Time (months) HR=1.07 (95% CI: ) P =0.678 Placebo 10.8 mos Pemetrexed 9.9 mos Time (months) 10
11 Systemic Post-study Therapy Pemetrexed (N=441) % Placebo (N=222) % Patients with post-study therapy Most common post-study therapies Carboplatin 7 10 Cisplatin 5 6 Docetaxel Erlotinib Gefitinib Gemcitabine 9 14 Paclitaxel 4 6 Pemetrexed 1 19 Vinorelbine Higher rate of follow-up treatment on the placebo arm Balanced selection of therapies between arms and low rate of crossover SATURN Phase III trial of Maintenance Erlotinib in Non- Progressors following 1 st Line Platinum-based Chemotherapy Chemonaïve advanced NSCLC n=1,949 Mandatory tumour sampling Stratification factors: 4 cycles of firstline platinum doublet chemotherapy* EGFR IHC (positive vs negative vs indeterminate) Stage (IIIB vs IV) ECOG PS (0 vs 1) CT regimen (cis/gem vs carbo/doc vs others) Smoking history (current vs former vs never) Region Non-PD n=889 Erlotinib 150mg/day 1:1 Placebo Co-primary endpoints: PD PD PFS in all patients PFS in patients with EGFR IHC+ tumours Secondary endpoints: OS in all patients and those with EGFR IHC+ tumours, OS and PFS in EGFR IHC tumours; biomarker analyses; safety; time to symptom progression; QoL *Cisplatin/paclitaxel; cisplatin/gemcitabine; cisplatin/docetaxel cisplatin/vinorelbine; carboplatin/gemcitabine; carboplatin/docetaxel carboplatin/paclitaxel Cappuzzo F et al. ASCO 2009, abstr #
12 PFS probability 1.0 SATURN PFS*: all patients HR=0.71 ( ) Log-rank p< Erlotinib Placebo PFS at 12 wks (%) PFS at 24 wks (%) Erlotinib (n=437) Placebo (n=447) Time (weeks) *PFS is measured from time of randomisation into the maintenance phase; assessments were every 6 weeks; ITT = intent-to-treat population SATURN OS*: all patients 1.0 OS probability HR=0.81 ( ) Log-rank p= Erlotinib (n=438) Placebo (n=451) Time (months) *OS is measured from time of randomisation into the maintenance phase; ITT = intent-to-treat population 12
13 SATURN Post-study treatment Erlotinib (n=438) Placebo (n=451) % with at least one treatment All classes taxanes (including docetaxel) antimetabolites (including pemetrexed) antineoplastic agents tyrosine-kinase inhibitors platinum compounds 9 12 ATLAS Phase III trial of Maintenance Erlotinib in Non- Progressors following 1 st Line Platinum-based Chemotherapy Combined with Avastin (Bevacizumab) Miller V et al. ASCO 2009, abstr # 8002 Chemo-naïve advanced NSCLC N=1,160 Eligibility 4 cycles of 1st-line chemotherapy* + bevacizumab Stage IIIB**/IV NSCLC ECOG performance status 0-1 Stratification factors Gender Smoking history (never vs former/current) ECOG performance status (0 v >1) Chemotherapy regimen Non-PD n=768 (66%) Bevacizumab (15mg/kg) + erlotinib (150mg) to PD 1:1 Bevacizumab + placebo to PD Primary endpoint Unblind at PD PFS in all randomized pts Secondary endpoints Overall survival Safety Exploratory endpoints Post progression therapy Biomarker analyses (IHC, FISH, EGFR & K-Ras mutation) *Carbo/paclitaxel; cis/vinorelbine; carbo or cis/gemcitabine; carbo or cis/docetaxel. **IIIB with pleural effusion 26 13
14 ATLAS: Progression-Free Survival 1.0 Proportion Without Event Bev + Placebo (n=373) Bev + Erlotinib (n=370) HR=0.722 ( ) Log-rank P= No. of patients at risk: Progression-Free Survival (months) Bev + Placebo Bev + Erlotinib Exposure to multiple lines of therapy on the JMEN, SATURN & ATLAS Trials JMEN SATURN ATLAS Pem Placebo Erlotinib Placebo Erlotinib Placebo % rec ing 1 st line % rec ing 2 nd line % rec ing 3 rd line NR 55 NR 50 NR 14
15 1 st to 2 nd Line Transition On JMEN, SATURN and ATLAS, patients were followed q3 weeks and evaluated radiographically q6 weeks Despite this, 33-45% did not receive 2 nd line therapy Reasons must be explored (one concern with regard to this issue is waiting for clear evidence of PD) What are the characteristics of these patients? Can we identify which patients will progress rapidly off therapy? Will early treatment make a difference? Can we identify which patients can safely have a treatment break & delay the benefit of 2 nd line therapy? Efficacy Outcomes in Trials of Sequential Versus Delayed 2 nd line Therapy # pts (entered/rand after 4 cycles) RR (%) Rx vs control DCR (%) Rx vs control PFS HR (p value) Fidias JMEN SATURN ATLAS 562/307 (55%)?/663 (?) 1949/889 (46%) 1160/768 (66%) 11 vs 11* 3 vs 1 12 vs 5 NR 67 vs 56* 49 vs vs 51 NR NR (<0.0001) 0.60 (< ) 0.71 (<0.0001) 0.72 (0.0012) in Med PFS 3.7 months 2 months 1 week 1 month OS HR (p value) NR (0.085) 0.79 (0.012) 0.81 (o.oo8) in MST 2.6 months 2.8 months 1 month NR NR * Compares patients treated on the immediate vs delayed docetaxel arms 15
16 The Changing Treatment Paradigm in Advanced NSCLC Standard of Care OBSERVE 1 st Line Rx 2 nd Line Rx ~30 40% Never Rx Should we rethink this? The Changing Treatment Paradigm in Advanced NSCLC Standard of Care OBSERVE 1 st Line Rx 2 nd Line Rx ~30 40% Never Rx New Alternative 1 st Line Rx Should we rethink this? 2 nd Line Rx 95% Rx 16
17 The Changing Treatment Paradigm in Advanced NSCLC Standard of Care 1 st Line Rx New Alternative OBSERVE Should we rethink this? 1 st Line Rx 2 nd Line Rx > Fidias Docetaxel Ciuleanu Pemetrexed SATURN Erlotinib ATLAS Erlotinib 2 nd Line Rx ~30 40% Never Rx All approved 2 nd line agents The Changing Treatment Paradigm in Advanced NSCLC Standard of Care OBSERVE 1 st Line Rx 2 nd Line Rx ~30 40% Never Rx Should we rethink this? Rx Break 1 st Line Rx? Surveillance? > Fidias Docetaxel Ciuleanu Pemetrexed SATURN Erlotinib ATLAS Erlotinib 2 nd Line Rx All approved 2 nd line agents 17
18 Survival for Patients Actually Receiving Docetaxel on Immediate & Delayed Arms (Fidias) MST (months) N Immediate Delayed My Conclusions Patients randomized to the maintenance or early treatment arms of these trials were exposed more often to effective chemotherapy Patients randomized to the placebo arms less often rec d 2 nd and presumably 3 rd line therapy A benefit in PFS and OS using agents approved for 2 nd line therapy in Rx-sensitive patients is not surprising (we already know this from BR.21 and TAX317) If 2 nd line therapy is delayed but delivered, survival outcomes may not be compromised (need more data from JMEN, SATURN and ATLAS) 18
19 My Conclusions It seems intuitive that exposure of more patients to multiple lines of effective therapy will improve survival Heightened surveillance allowing 2 nd /3 rd line therapy to be administered early seems reasonable but carries a risk Sequencing to approved 2 nd line agents immediately following 1 st line therapy will increase exposure to multiple lines of therapy This strategy does improve PFS and OS in advanced NSCLC Maintenance Therapy in Advanced NSCLC When? After 4 cycles of chemo in non-progressors Who? Patients you are worried about What? Docetaxel, Pemetrexed (non-squames), Erlotinib Why? Phase III data showing PFS and OS benefit What s Left? Whatever you did not already use 19
20 We depend on your support to continue GRACE educational programs like these. PLEASE contribute at 20
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationMaintenance therapies in advanced non-small-cell lung cancer
Review Maintenance therapies in advanced non-small-cell lung cancer Advanced non-small-cell lung cancer is treated with upfront platinum doublet chemotherapy, which produces moderate survival improvements.
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationIs there a role for maintenance therapy in advanced non-small-cell lung cancer?
Review Is there a role for maintenance therapy in advanced non-small-cell lung cancer? Cesare Gridelli*1, Paolo Maione1, Antonio Rossi1, Clorinda Schettino1, Maria Anna Bareschino1, Paola Claudia Sacco1,
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationCytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion
Cytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion Corey J Langer MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor of Medicine Hematology-Oncology
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationReview on activated protocols in advanced non-small cell lung cancer. Rolf Stahel Zürich, Switzerland
Review on activated protocols in advanced non-small cell lung cancer Rolf Stahel Zürich, Switzerland Lucerne, 19.1.2008 Case report 1 75 y/o man retired, held many jobs from working as driver, attendant
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationCollaborative Practice in the Management of Patients With Cancer. Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy
Collaborative Practice in the Management of Patients With Cancer Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy Program Chair Beth Eaby-Sandy, MSN, CRNP, OCN Abramson Cancer
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationΕλλάδα Ελευθεριάδου Ειδικός Πνευμονολόγος Επιστημονική συνεργάτης της Πνευμονολογικής Κλινικής ΑΠΘ Νοσοκομείου Παπανικολάου και υποψήφια διδάκτορας
Ελλάδα Ελευθεριάδου Ειδικός Πνευμονολόγος Επιστημονική συνεργάτης της Πνευμονολογικής Κλινικής ΑΠΘ Νοσοκομείου Παπανικολάου και υποψήφια διδάκτορας ΑΠΘ Μετεγχειριτική αντιμετώπιση του ΜΜΚΠ Significant
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationdoi: /theoncologist originally published online February 3, 2009
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line? Cesare Gridelli, Paolo Maione, Antonio Rossi, Marianna Luciana Ferrara, Maria Anna
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More informationEGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?
Review Article EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? Robert Pirker Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria Corresponding
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationThe lifetime risk of developing lung cancer is 1 in 13 for men and 1 in 16 for women.
6 Oncology & Biotech News 07.09 Special ASCO Highlights Issue The National Cancer Institute estimates there will be 219,440 new cases of lung cancer diagnosed in the United States in 2009 and 159,390 deaths.
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More information